Home » Topics » Drugs » Immuno-oncology

Immuno-oncology
RSS

Dendreon describes preparation and use of apoptosis-inducing HLA-DR-specific MAbs

April 10, 2000

Health Canada approves Rituxan for treatment of NHL

April 7, 2000

Oncolytics Biotech's pilot canine study of Reolysin shows measurable tumor response

April 4, 2000

Avax begins phase II study of M-Vax in stage IV metastatic melanoma

April 3, 2000

AltaRex presents clinical plan for OvaRex at BIO 2000 annual meeting

March 30, 2000

SRL-172 associated with significantly improved survival in SCLC patients

March 28, 2000

Phase I clinical study to begin with Reolysin as cancer treatment

March 27, 2000

FDA grants orphan drug status to Zadaxin for treatment of liver cancer

March 24, 2000

Phase I study of AltaRex's BrevaRex MAb completed

March 22, 2000

StressGen initiates phase II study with HspE7 in high-grade cervical dysplasia

March 22, 2000

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for July 6, 2026.
CINP 2026: Prenatal and adolescent stress shape brain vulnerability
BioWorld Science
Human biology is extraordinarily complex, and that sophistication emerges from the very beginning. During embryonic and fetal development, the organism’s...
Ontrack Therapeutics divulges compounds for neurodegenerative diseases
BioWorld Science
Ontrack Therapeutics Ltd. has reported new heterotricyclic compounds potentially useful for the treatment of neurodegenerative diseases.
Neuracle eyes Shanghai IPO as global BCI funding surges
BioWorld
Neuracle Medical Technology Co. Ltd. is seeking a Shanghai IPO that could make it China’s first publicly listed invasive brain-computer interface (BCI) company,...
Neurovalens granted FDA approval for PTSD therapy for US veterans
BioWorld
Veterans in the U.S. suffering from post-traumatic stress disorder (PTSD) now have access to Neurovalens Ltd.’s Modius Spero, a wearable neuromodulation device,...